WD-890

WD-890 is a novel, potent, and selective allosteric inhibitor of tyrosine kinase 2 (TYK2), a member of the Janus kinase (JAK) family. It binds to the pseudokinase (JH2) domain of TYK2 with high selectivity, inhibiting its function and thereby modulating signaling pathways mediated by type I interferons (IFN), interleukin-12 (IL-12), and interleukin-23 (IL-23). These pathways are implicated in various immune and inflammatory diseases. Preclinical studies have demonstrated that WD-890 has therapeutic efficacy in animal models of systemic lupus erythematosus (SLE), psoriasis, psoriatic arthritis (PsA), and inflammatory bowel disease (IBD). The compound exhibits favorable pharmacokinetic properties and tolerable toxicity profiles, supporting its potential as an oral treatment for multiple autoimmune diseases[1][2][4].